WHO Sounds Alert Over Severe Lack of Weight-Loss Jabs

Under 10% of patients who could benefit from obesity jabs such as Wegovy are able to get them, caution the WHO as it publishes its initial advice on the medications.

Given more than one billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer access to these injectable treatments.

Per projections, more than two billion could be obese by 2030 unless action is taken.

"The latest guidelines affirms that excess weight is a chronic disease that can be treated with thorough and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and distribution challenges are significant obstacles to broad access to the injections that can help people shift substantial body mass, says the organization.

Skinny Jab Supply Crisis

Even in the current most favorable outlook, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – fewer than 10% of the global need, as stated by the health organization.

The recommendation urges countries and companies to increase access, by measures such as voluntary licensing.

The intellectual property rights on semaglutide – the core component of a leading brand – is set to lapse in multiple nations in 2026.

The Way Obesity Injections Work

These medications replicate a body's own hormone to delay gastric emptying, suppress the appetite and increase feelings of fullness so individuals reduce food intake.

People commonly begin shedding pounds in the initial weeks of starting on the weekly injections.

Research points to people may see weight return within a year of discontinuing the drug, when their normal hunger return.

Being carrying excess weight elevates your risk for experiencing diseases, such as type 2 diabetes, heart disease, stroke, and certain malignancies.

Obesity affects individuals in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, as per the WHO.